CoLucid Pharmaceuticals (CLCD) PT Raised to $30 at Stifel
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Stifel analyst Annabel Samimy reiterated a Buy rating and bumped her price target on CoLucid Pharmaceuticals (NASDAQ: CLCD) to $30.00 (from $27.00) after the company reported additional data from its Phase 3 SAMURAI trial of lasmiditan in acute migraine. In addition to meeting all of its primary endpoints, lasmiditan demonstrated high statistical significance on most of its secondary endpoints, including: 1) headache relief at 2 hours, 2) headache freedom two hours after dosing when used as a second dose for rescue or recurrence, 3) the efficacy of lasmiditan on the Patient Global Impression of Change (PGIC), and 4) efficacy of lasmiditan based on migraine disability at 2 hours. Lasmiditan also achieved statistical significance on freedom from Most Bothersome Symptom (MBS) with the majority of patients choosing photophobia as MBS at baseline. On safety, the full data confirmed lasmiditan did not result in an increase in AEs or cardiovascular risk on the second dose.
Samimy commented, "Overall, we believe these data confirm the strong profile of lasmiditan on both efficacy and safety, and see the drug appropriate for a broad migraine patient population despite its specific utility in CV patients. Reiterate Buy, bumping up TP to $30."
Shares of CoLucid Pharmaceuticals closed at $28.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pivotal Research Downgrades Kroger (KR) to Hold
- Jefferies Raises Price Target on US Physical Therapy (USPH) to $63 Following 12-Clinic Acquisition
- JPMorgan Raises Rating on CBOE Holdings (CBOE) to 'Overweight'; Analyst Thinks Bats Technology Will Drive Greater Trading Activity
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!